{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:26:31Z","timestamp":1788830791682,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Neurobiol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10571-024-01511-3","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:41:47Z","timestamp":1731048107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Spinal Muscular Atrophy: Current Medications and Re-purposed Drugs"],"prefix":"10.1007","volume":"44","author":[{"given":"Soumyadutta","family":"Basak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nupur","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashaanka","family":"Ashili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"1511_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s00018-022-04408-w","volume":"79","author":"E Abati","year":"2022","unstructured":"Abati E, Manini A, Comi GP, Corti S (2022) Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases. Cell Mol Life Sci 79:374","journal-title":"Cell Mol Life Sci"},{"key":"1511_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.06.007","author":"SA Al-Zaidy","year":"2019","unstructured":"Al-Zaidy SA, Mendell JR (2019) From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. Pediatric Neurol. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.06.007","journal-title":"Pediatric Neurol"},{"key":"1511_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s12017-021-08660-4","volume":"23","author":"KV Athira","year":"2021","unstructured":"Athira KV et al (2021) Repurposing vorinostat for the treatment of disorders affecting brain. Neuromol Med 23:449\u2013465","journal-title":"Neuromol Med"},{"key":"1511_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","volume":"16","author":"E Bertini","year":"2017","unstructured":"Bertini E et al (2017) Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:513\u2013522","journal-title":"Lancet Neurol"},{"key":"1511_CR5","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.1007\/s00415-022-11231-7","volume":"269","author":"S Bonanno","year":"2022","unstructured":"Bonanno S et al (2022) Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial. J Neurol 269:5858\u20135867","journal-title":"J Neurol"},{"key":"1511_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1242\/dmm.030148","volume":"10","author":"M Bowerman","year":"2017","unstructured":"Bowerman M et al (2017) Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech 10:943","journal-title":"Dis Model Mech"},{"key":"1511_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.expneurol.2016.02.009","volume":"279","author":"MER Butchbach","year":"2016","unstructured":"Butchbach MER et al (2016) Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Exp Neurol 279:13\u201326","journal-title":"Exp Neurol"},{"key":"1511_CR8","doi-asserted-by":"publisher","first-page":"10067","DOI":"10.1021\/acs.jmedchem.6b00670","volume":"59","author":"AN Calder","year":"2016","unstructured":"Calder AN, Androphy EJ, Hodgetts KJ (2016) Small molecules in development for the treatment of spinal muscular atrophy. J Med Chem 59:10067","journal-title":"J Med Chem"},{"key":"1511_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/ng854","volume":"30","author":"L Cartegni","year":"2002","unstructured":"Cartegni L, Krainer AR (2002) Disruption of an SF2\/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 30:377\u2013384","journal-title":"Nat Genet"},{"key":"1511_CR10","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","volume":"2","author":"H Chaytow","year":"2021","unstructured":"Chaytow H, Faller KME, Huang Y-T, Gillingwater TH (2021) Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med 2:100346","journal-title":"Cell Rep Med"},{"key":"1511_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA et al (2016) Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy. Neurology 86:890\u2013897","journal-title":"Neurology"},{"key":"1511_CR12","doi-asserted-by":"publisher","first-page":"8962","DOI":"10.3390\/ijms22168962","volume":"22","author":"LC Chong","year":"2021","unstructured":"Chong LC, Gandhi G, Lee JM, Yeo WWY, Choi SB (2021) Drug discovery of spinal muscular atrophy (SMA) from the computational perspective: a comprehensive review. Int J Mol Sci 22:8962","journal-title":"Int J Mol Sci"},{"key":"1511_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1006\/nbdi.1996.0010","volume":"3","author":"TO Crawford","year":"1996","unstructured":"Crawford TO, Pardo CA (1996) The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 3:97\u2013110","journal-title":"Neurobiol Dis"},{"key":"1511_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Risdiplam: first approval. Drugs 80:1853\u20131858","journal-title":"Drugs"},{"key":"1511_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40263-019-00606-6","volume":"33","author":"A Elshafay","year":"2019","unstructured":"Elshafay A et al (2019) Efficacy and safety of valproic acid for spinal muscular atrophy: a systematic review and meta-analysis. CNS Drugs 33:239\u2013250","journal-title":"CNS Drugs"},{"key":"1511_CR16","doi-asserted-by":"publisher","DOI":"10.5772\/53800","author":"FT Farooq","year":"2013","unstructured":"Farooq FT et al (2013) Spinal muscular atrophy: classification, diagnosis, background, molecular mechanism and development of therapeutics. Neurodegener Dis. https:\/\/doi.org\/10.5772\/53800","journal-title":"Neurodegener Dis"},{"key":"1511_CR17","first-page":"714","volume":"52","author":"Y Feng","year":"2023","unstructured":"Feng Y et al (2023) Efficacy and safety of salbutamol in treatment of children with later-onset spinal muscular atrophy. Zhejiang Da Xue Xue Bao Yi Xue Ban 52:714\u2013720","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"1511_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6026\/97320630016001","volume":"16","author":"DR Flower","year":"2020","unstructured":"Flower DR (2020) Drug discovery: today and tomorrow. Bioinformation 16:1","journal-title":"Bioinformation"},{"key":"1511_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.nmd.2019.04.003","volume":"29","author":"AL Frongia","year":"2019","unstructured":"Frongia AL et al (2019) Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II. Neuromuscul Disord 29:517\u2013524","journal-title":"Neuromuscul Disord"},{"key":"1511_CR20","unstructured":"Genentech: Press Releases | Friday, Aug 7, 2020. https:\/\/www.gene.com\/media\/press-releases\/14866\/2020-08-07\/fda-approves-genentechs-evrysdi-risdipla."},{"key":"1511_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00045","author":"N Hensel","year":"2020","unstructured":"Hensel N, Kubinski S, Claus P (2020) The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.00045","journal-title":"Front Neurol"},{"key":"1511_CR22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/hmg\/ddad192","volume":"33","author":"JM Hoolachan","year":"2024","unstructured":"Hoolachan JM et al (2024) A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) models. Hum Mol Genet 33:400\u2013425","journal-title":"Hum Mol Genet"},{"key":"1511_CR23","doi-asserted-by":"crossref","unstructured":"Hoolachan J, Sutton E, Neurology MBF (2019) Teaching an old drug new tricks: repositioning strategies for spinal muscular atrophy. Future Medicine 14","DOI":"10.2217\/fnl-2019-0006"},{"key":"1511_CR24","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes JP et al (2011) Principles of early drug discovery. Br J Pharmacolgy 162:1239\u20131249","journal-title":"Br J Pharmacolgy"},{"key":"1511_CR25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/ng1207","volume":"34","author":"T Kashima","year":"2003","unstructured":"Kashima T, Manley JL (2003) A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet 34:460\u2013463","journal-title":"Nat Genet"},{"key":"1511_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath MC, Prior DE, Prior TW (2021) Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet 14:11\u201325","journal-title":"Appl Clin Genet"},{"key":"1511_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pediatrneurol.2017.04.013","volume":"73","author":"S Khirani","year":"2017","unstructured":"Khirani S et al (2017) Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy. Pediatr Neurol 73:78-87.e1","journal-title":"Pediatr Neurol"},{"key":"1511_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.nmd.2013.10.011","volume":"24","author":"J Kirschner","year":"2014","unstructured":"Kirschner J et al (2014) Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study. Neuromuscul Disord 24:134\u2013142","journal-title":"Neuromuscul Disord"},{"key":"1511_CR29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"SJ Kolb","year":"2011","unstructured":"Kolb SJ, Kissel JT (2011) Spinal muscular atrophy: a timely review. Arch Neurol 68:979\u2013984","journal-title":"Arch Neurol"},{"key":"1511_CR30","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1096\/fj.201802554RRR","volume":"34","author":"P Konieczny","year":"2020","unstructured":"Konieczny P, Artero R (2020) Drosophila SMN2 minigene reporter model identifies moxifloxacin as a candidate therapy for SMA. FASEB J 34:3021\u20133036","journal-title":"FASEB J"},{"key":"1511_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1134\/S1068162023020139","volume":"49","author":"VS Kulkarni","year":"2023","unstructured":"Kulkarni VS, Alagarsamy V, Solomon VR, Jose PA, Murugesan S (2023) Drug repurposing: an effective tool in modern drug discovery. Russ J Bioorg Chem 49:157\u2013166","journal-title":"Russ J Bioorg Chem"},{"key":"1511_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0724-z","author":"C Lally","year":"2017","unstructured":"Lally C et al (2017) Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-017-0724-z","journal-title":"Orphanet J Rare Dis"},{"key":"1511_CR33","doi-asserted-by":"publisher","first-page":"115425","DOI":"10.1016\/j.bmc.2020.115425","volume":"28","author":"CA Lipinski","year":"2020","unstructured":"Lipinski CA, Reaume AG (2020) High throughput in vivo phenotypic screening for drug repurposing: discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept. Bioorg Med Chem 28:115425","journal-title":"Bioorg Med Chem"},{"key":"1511_CR34","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH (2008) Spinal muscular atrophy. Lancet 371:2120\u20132133","journal-title":"Lancet"},{"key":"1511_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","volume":"9","author":"R Mahajan","year":"2019","unstructured":"Mahajan R (2019) Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever. Int J Appl Basic Med Res 9:127","journal-title":"Int J Appl Basic Med Res"},{"key":"1511_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/0884217503261125","volume":"33","author":"JA Markowitz","year":"2004","unstructured":"Markowitz JA, Tinkle MB, Fischbeck KH (2004) Spinal muscular atrophy in the neonate. J Obstet Gynecol Neonatal Nurs 33:12\u201320","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"1511_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.149446","author":"KE Meijboom","year":"2021","unstructured":"Meijboom KE et al (2021) Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.149446","journal-title":"JCI Insight"},{"key":"1511_CR38","doi-asserted-by":"publisher","first-page":"592234","DOI":"10.3389\/fphar.2020.592234","volume":"11","author":"G Menduti","year":"2020","unstructured":"Menduti G, Ras\u00e0 DM, Stanga S, Boido M (2020) Drug screening and drug repositioning as promising therapeutic approaches for spinal muscular atrophy treatment. Front Pharmacol 11:592234","journal-title":"Front Pharmacol"},{"key":"1511_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/08830738030180080501","volume":"18","author":"L Merlini","year":"2003","unstructured":"Merlini L et al (2003) Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol 18:537\u2013541","journal-title":"J Child Neurol"},{"key":"1511_CR40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","volume":"191","author":"RG Miller","year":"2001","unstructured":"Miller RG et al (2001) A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 191:127\u2013131","journal-title":"J Neurol Sci"},{"key":"1511_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1590\/S1415-47572013000300001","volume":"36","author":"J Mohseni","year":"2013","unstructured":"Mohseni J, Zabidi-Hussin ZAMH, Sasongko TH (2013) Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy. Genet Mol Biol 36:299\u2013307","journal-title":"Genet Mol Biol"},{"key":"1511_CR42","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.nmd.2020.10.008","volume":"30","author":"F Muntoni","year":"2020","unstructured":"Muntoni F et al (2020) Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscul Disord 30:959\u2013969","journal-title":"Neuromuscul Disord"},{"key":"1511_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/90765","volume":"19","author":"S Myers","year":"2001","unstructured":"Myers S, Baker A (2001) Drug discovery\u2014an operating model for a new era. Nat Biotechnol 19:727\u2013730","journal-title":"Nat Biotechnol"},{"key":"1511_CR44","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.1250127","volume":"345","author":"NA Naryshkin","year":"2014","unstructured":"Naryshkin NA et al (2014) Motor neuron disease: SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345:688\u2013693","journal-title":"Science"},{"key":"1511_CR45","doi-asserted-by":"crossref","unstructured":"Nishio H et al (2023) Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci 24","DOI":"10.3390\/ijms241511939"},{"key":"1511_CR46","doi-asserted-by":"publisher","first-page":"e0201764","DOI":"10.1371\/journal.pone.0201764","volume":"13","author":"N Otsuki","year":"2018","unstructured":"Otsuki N et al (2018) A new biomarker candidate for spinal muscular atrophy: identification of a peripheral blood cell population capable of monitoring the level of survival motor neuron protein. PLoS ONE 13:e0201764","journal-title":"PLoS ONE"},{"key":"1511_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/jnc.14935","volume":"153","author":"V Pagliarini","year":"2020","unstructured":"Pagliarini V, Guerra M, Di Rosa V, Compagnucci C, Sette C (2020) Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells. J Neurochem 153:264\u2013275","journal-title":"J Neurochem"},{"key":"1511_CR48","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nchembio.1837","volume":"11","author":"J Palacino","year":"2015","unstructured":"Palacino J et al (2015) SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice. Nat Chem Biol 11:511\u2013517","journal-title":"Nat Chem Biol"},{"key":"1511_CR49","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.nmd.2008.05.004","volume":"18","author":"M Pane","year":"2008","unstructured":"Pane M et al (2008) Daily salbutamol in young patients with SMA type II. Neuromuscul Disord 18:536\u2013540","journal-title":"Neuromuscul Disord"},{"key":"1511_CR50","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/jnc.14974","volume":"153","author":"A Poletti","year":"2020","unstructured":"Poletti A, Fischbeck KH (2020) Combinatorial treatment for spinal muscular atrophy: an editorial for combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense. J Neurochem 153:146\u2013149","journal-title":"J Neurochem"},{"key":"1511_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-816125-8.00002-X","volume-title":"Computational drug design methods\u2014current and future perspectives","author":"FD Prieto-Mart\u00ednez","year":"2019","unstructured":"Prieto-Mart\u00ednez FD, L\u00f3pez-L\u00f3pez E, Ju\u00e1rez-Mercado KE, Medina-Franco JL (2019) Computational drug design methods\u2014current and future perspectives. Elsevier"},{"key":"1511_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S et al (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41\u201358","journal-title":"Nat Rev Drug Discov"},{"key":"1511_CR53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","volume":"21","author":"S Ramdas","year":"2020","unstructured":"Ramdas S, Servais L (2020) New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother 21:307\u2013315","journal-title":"Expert Opin Pharmacother"},{"key":"1511_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/13543784.2021.1904889","volume":"30","author":"L Servais","year":"2021","unstructured":"Servais L, Baranello G, Scoto M, Daron A, Oskoui M (2021) Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opin Investig Drugs 30:519\u2013527","journal-title":"Expert Opin Investig Drugs"},{"key":"1511_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40265-018-0868-8","volume":"78","author":"HK Shorrock","year":"2018","unstructured":"Shorrock HK, Gillingwater TH, Groen EJN (2018) Overview of current drugs and molecules in development for spinal muscular atrophy therapy. Drugs 78:293\u2013305","journal-title":"Drugs"},{"key":"1511_CR56","doi-asserted-by":"publisher","first-page":"e019932","DOI":"10.1136\/bmjopen-2017-019932","volume":"8","author":"M Stam","year":"2018","unstructured":"Stam M et al (2018) Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2\u20134 (SPACE trial). BMJ Open 8:e019932","journal-title":"BMJ Open"},{"key":"1511_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac324","author":"M Stam","year":"2022","unstructured":"Stam M et al (2022) Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2\u20134. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcac324","journal-title":"Brain Commun"},{"key":"1511_CR58","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1172\/JCI121658","volume":"128","author":"CJ Sumner","year":"2018","unstructured":"Sumner CJ, Crawford TO (2018) Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest 128:3219","journal-title":"J Clin Invest"},{"key":"1511_CR59","doi-asserted-by":"publisher","first-page":"8691","DOI":"10.1523\/JNEUROSCI.0417-15.2015","volume":"35","author":"S Tisdale","year":"2015","unstructured":"Tisdale S, Pellizzoni L (2015) Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci 35:8691","journal-title":"J Neurosci"},{"key":"1511_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006282.pub5","author":"RI Wadman","year":"2020","unstructured":"Wadman RI et al (2020) Drug treatment for spinal muscular atrophy types II and III. Cochrane Database System Rev. https:\/\/doi.org\/10.1002\/14651858.CD006282.pub5","journal-title":"Cochrane Database System Rev"},{"key":"1511_CR61","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/S0960-8966(99)00016-4","volume":"9","author":"K Zerres","year":"1999","unstructured":"Zerres K, Davies KE (1999) 59th ENMC international workshop: spinal muscular atrophies: recent progress and revised diagnostic criteria 17\u201319 April 1998, soestduinen. The Netherlands Neuromuscul Disord 9:272\u2013278","journal-title":"The Netherlands Neuromuscul Disord"},{"key":"1511_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K et al (1997) A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci 146:67\u201372","journal-title":"J Neurol Sci"},{"key":"1511_CR63","unstructured":"Zolgensma | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma#product-information-section"}],"container-title":["Cellular and Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-024-01511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10571-024-01511-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10571-024-01511-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T07:04:44Z","timestamp":1734159884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10571-024-01511-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1511"],"URL":"https:\/\/doi.org\/10.1007\/s10571-024-01511-3","relation":{},"ISSN":["0272-4340","1573-6830"],"issn-type":[{"value":"0272-4340","type":"print"},{"value":"1573-6830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study does not require any ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}],"article-number":"75"}}